OS Animal Health Shows Positive Phase 2 Results for OST-HER2
Rockville, Maryland, June 26, 2026 OS Animal Health announced the peer-reviewed publication of Phase 2 clinical trial results evaluating...
OS Therapies
Advertisement
OS Therapies Advances OST-HER2 Ahead of ASCO 2026 Presentation
NEW YORK and ROCKVILLE, Md., May 29, 2026 OS Therapies announced the publication of four scientific articles focused on...
OS Therapies Secures EMA Review for OST-HER2 Drug
NEW YORK, New York, April 30, 2026 OS Therapies announced that the European Medicines Agency (EMA) has initiated a...
OS Therapies Advances OST-HER2 Toward FDA Approval
NEW YORK, March 31, 2026 — OS Therapies, Inc a clinical-stage oncology company specializing in listeria-based cancer immunotherapies, has...
OS Therapies Advances OST-HER2 Toward Phase 3 Trial
New York, March 27, 2026 OS Therapies has achieved a significant regulatory milestone by securing meetings with multiple global...
Advertisements
OS Therapies Gains Key FDA & EMA Milestones for OST-HER2 Immunotherapy
NEW YORK, NY — December 5, 2025 — OS Therapies Inc. announced two major regulatory milestones advancing its lead...
OS Therapies Spins Off OS Animal Health as New Veterinary Biotech
ROCKVILLE, MD — November 20, 2025 — OS Therapies announced the strategic spin-off of OS Animal Health, establishing it...
OS Therapies Accelerates OST-HER2 Toward 2026 BLA with Strong Q3 Progress
Dateline: November 17, 2025 — New York, NYOS Therapies reported its third-quarter 2025 financial results and issued a comprehensive...
OS Therapies Reports 75% Two-Year Survival in Osteosarcoma Immunotherapy Trial
New York, NY – October 10, 2025 – OS Therapies Inc. has announced statistically significant positive final results from...
Advertisement
